UBS Group AG Cuts Holdings in Olema Pharmaceuticals, Inc. $OLMA

UBS Group AG lowered its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 75.3% in the 4th quarter, HoldingsChannel reports. The fund owned 293,560 shares of the company’s stock after selling 897,094 shares during the period. UBS Group AG’s holdings in Olema Pharmaceuticals were worth $7,339,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Russell Investments Group Ltd. purchased a new position in Olema Pharmaceuticals in the third quarter worth about $53,000. American Century Companies Inc. purchased a new position in Olema Pharmaceuticals in the second quarter worth about $54,000. Creative Planning purchased a new position in Olema Pharmaceuticals in the second quarter worth about $83,000. Nisa Investment Advisors LLC grew its position in Olema Pharmaceuticals by 14.5% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,764 shares of the company’s stock worth $94,000 after acquiring an additional 477 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Olema Pharmaceuticals by 44.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,822 shares of the company’s stock worth $96,000 after acquiring an additional 1,169 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Down 5.1%

Shares of NASDAQ OLMA opened at $12.90 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. The company has a market cap of $1.13 billion, a P/E ratio of -6.39 and a beta of 2.05. Olema Pharmaceuticals, Inc. has a 1 year low of $3.89 and a 1 year high of $36.26. The firm has a 50-day simple moving average of $15.19 and a two-hundred day simple moving average of $20.55.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.52). Research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.19 earnings per share for the current year.

Insider Buying and Selling at Olema Pharmaceuticals

In other news, insider Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $24.25, for a total transaction of $606,250.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 12.56% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. TD Cowen reiterated a “buy” rating on shares of Olema Pharmaceuticals in a research report on Monday, March 9th. JPMorgan Chase & Co. lifted their price target on Olema Pharmaceuticals from $55.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 18th. Stifel Nicolaus assumed coverage on Olema Pharmaceuticals in a research report on Wednesday, February 11th. They issued a “buy” rating and a $48.00 price target for the company. The Goldman Sachs Group dropped their price target on Olema Pharmaceuticals from $38.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday, March 18th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Tuesday, April 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.